Daiichi Sankyo Europe Highlights Broad EAS Congress 2026 Data Presentations Supporting Patient-Centred Cardiovascular Care
Daiichi Sankyo Europe has announced a major scientific presence at the upcoming European Atherosclerosis Society Congress 2026, highlighting the company’s continued commitment to advancing cardiovascular care and improving lipid management across diverse patient populations. Through the presentation of 15 scientific abstracts, the company aims to showcase new clinical insights and real-world evidence supporting the use of bempedoic acid in patients with dyslipidemia and elevated cardiovascular risk.
The extensive data package reflects Daiichi Sankyo Europe’s ongoing investment in cardiovascular research and its broader mission to improve outcomes for patients living with heart disease and cholesterol disorders. The presentations include findings from major clinical trials, post-hoc analyses, registry studies, and observational research conducted across several European countries. Collectively, the data are designed to provide healthcare professionals with a deeper understanding of how bempedoic acid performs in both controlled clinical settings and routine real-world medical practice.
Cardiovascular disease remains one of the leading causes of death globally, with elevated low-density lipoprotein cholesterol (LDL-C) recognized as a major modifiable risk factor for heart attacks, strokes, and other cardiovascular complications. Despite the availability of several lipid-lowering therapies, a substantial number of patients across Europe continue to fall short of recommended LDL-C targets, leaving them vulnerable to long-term cardiovascular events.
Daiichi Sankyo Europe’s scientific presentations at EAS Congress 2026 place significant focus on addressing these treatment gaps. Many of the analyses being presented evaluate how bempedoic acid may help patients lower LDL-C levels regardless of their background therapy, treatment history, or clinical profile.
A major component of the company’s scientific program centers around the MILOS registry, a multinational real-world observational study designed to assess the effectiveness and safety of bempedoic acid in routine clinical practice. Data from the MILOS program include findings from several European countries, providing clinicians with insights into how the therapy performs outside the highly controlled environment of randomized clinical trials.
Among the presentations is a one-year analysis of real-world experience with bempedoic acid in patients with dyslipidemia from the United Kingdom cohort of the MILOS study. Additional data from Italy, Belgium, Austria, Spain, and Switzerland further contribute to a growing body of evidence demonstrating the therapy’s effectiveness and safety across multiple healthcare systems and patient populations.
Researchers involved in the MILOS analyses reported consistent LDL-C reductions among patients treated with bempedoic acid, regardless of whether the medication was used alone or in combination with background lipid-lowering therapies such as statins or ezetimibe. This finding is considered particularly important for patients who are unable to tolerate high-intensity statin therapy or who require additional LDL-C lowering beyond standard treatment approaches.
The real-world evidence presented through the MILOS registry also highlights the practical application of bempedoic acid in routine care settings, where patient adherence, comorbidities, and varying treatment regimens often influence outcomes. By demonstrating consistent performance across different countries and healthcare environments, the data may help clinicians feel more confident incorporating the therapy into individualized treatment strategies.
Another important area of focus at EAS Congress 2026 is the ongoing analysis of data from the Phase 3 CLEAR Outcomes study. Conducted in collaboration with Esperion Therapeutics, the CLEAR Outcomes trial has become one of the most significant studies evaluating cardiovascular outcomes in statin-intolerant patients.
Several post-hoc analyses from CLEAR Outcomes will be presented during the congress. One analysis examines factors associated with enhanced LDL cholesterol lowering in patients treated with bempedoic acid. Researchers hope these findings will help identify patient characteristics associated with stronger treatment responses and guide more personalized lipid-lowering strategies.
Additional analyses explore the relationship between bempedoic acid and the incidence of venous thromboembolism (VTE), as well as the therapy’s impact on stroke incidence among statin-intolerant patients. These investigations are particularly relevant because cardiovascular risk management extends beyond cholesterol reduction alone and includes the prevention of broader vascular complications.
One secondary analysis from CLEAR Outcomes evaluates patients who received bempedoic acid without concurrent background lipid-lowering therapy. The findings may offer important insights into the standalone benefits of the medication in reducing LDL cholesterol and cardiovascular events, particularly for patients who cannot tolerate conventional statin treatment.
Beyond adult populations, Daiichi Sankyo Europe is also highlighting new research involving pediatric patients with familial hypercholesterolemia. Data from the CLEAR Path 1 trial will examine the use of bempedoic acid in children aged 6 to 17 years with heterozygous familial hypercholesterolemia, a genetic disorder characterized by significantly elevated LDL cholesterol levels from an early age.
Familial hypercholesterolemia is associated with a markedly increased lifetime risk of premature cardiovascular disease if left untreated. Early diagnosis and aggressive LDL-C management are therefore considered essential for improving long-term outcomes. The pediatric study reflects broader efforts within the cardiovascular community to expand evidence-based treatment options for younger patients living with inherited lipid disorders.
Daiichi Sankyo Europe noted that the pediatric research complements recent regulatory updates concerning breastfeeding considerations associated with bempedoic acid use. Updated prescribing information now indicates that therapy may be considered during breastfeeding when the potential benefit to the mother outweighs the benefits of breastfeeding for the child. The company said these developments underscore its commitment to evaluating the therapy across a broad range of patient populations, including groups that have historically been underserved in cardiovascular research.
Professor Maurizio Averna, Professor of Internal Medicine at the University of Palermo, emphasized the importance of the real-world evidence being presented at the congress. According to Averna, many patients throughout Europe continue to miss recommended LDL-C targets despite available therapies, exposing them to avoidable cardiovascular risk.
He explained that the data emerging from the MILOS registry may provide clinicians with valuable practical evidence that can help bridge existing treatment gaps in routine care and support improved outcomes across diverse patient populations.
Dr. Stefan Seyfried, Vice President and Head of Medical Affairs for Specialty Medicines at Daiichi Sankyo Europe, stated that the company’s commitment extends beyond generating clinical data alone. He emphasized that the company’s cardiovascular research strategy is centered on improving the patient journey and ensuring broader access to effective lipid management solutions.
According to Seyfried, the large scientific program being presented at EAS Congress 2026 demonstrates the company’s sustained investment in cardiovascular medicine and reinforces its mission to help patients achieve their treatment goals through innovative, evidence-based therapies.
The company believes that the growing evidence base surrounding bempedoic acid may help support more informed treatment decisions among healthcare professionals, particularly as physicians seek additional options for patients who remain at elevated cardiovascular risk despite current therapy.
As cardiovascular disease continues to represent a major public health challenge worldwide, the presentations at EAS Congress 2026 highlight the increasing importance of personalized lipid management strategies and the role of emerging therapies in helping patients achieve recommended cholesterol targets. Through its broad scientific program, Daiichi Sankyo Europe aims to contribute to the evolving understanding of cardiovascular prevention and reinforce the importance of comprehensive, patient-centered care in reducing long-term cardiovascular risk.
About MILOS
MILOS (NCT04579367) is an ongoing, multinational, European observational study in adult patients diagnosed with primary hypercholesterolaemia or mixed dyslipidaemia.11 The aim is to evaluate the real-world use of bempedoic acid and bempedoic plus ezetimibe fixed-dose combination. Beyond Germany, MILOS has sites in Austria, Belgium, Italy, the Netherlands, Spain, Switzerland and the UK.11
About CLEAR Outcomes trial
The CLEAR Outcomes trial was a double‑blind, randomized, placebo‑controlled study designed to evaluate the effect of bempedoic acid on cardiovascular (CV) outcomes in statin‑intolerant patients for whom primary or secondary CV prevention was clinically indicated.12 The trial enrolled 13,970 patients aged 18–85 years (mean age 65.5 years), nearly half of whom were women, all of whom had established or were at high risk for cardiovascular disease and a mean baseline LDL‑C of 139 mg/dL (3.59 mmol/L).12
Conducted at 1,250 sites across 32 countries, patients were randomized to receive oral bempedoic acid 180 mg daily or placebo and were followed for a median of 40.6 months.12 The primary endpoint was a four‑component composite of major adverse cardiovascular events (MACE‑4): CV death, non‑fatal myocardial infarction, non‑fatal stroke, or coronary revascularization, with multiple key secondary CV endpoints also assessed.12
About Daiichi Sankyo
Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society.
